On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the Company) completed the transactions contemplated by the Agreement and Plan of Merger, dated as of May 9, 2022 (the Merger Agreement"), by and among Pfizer Inc. (Pfizer), Bulldog (BVI) Ltd. (Merger Sub) and the Company. Pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Pfizer. In accordance with the Merger Agreement, at the Effective Time, each of Irina A. Antonijevic, Gregory Bailey, Matthew Buten, John W. Childs, George Clark, Charles Conway, Vlad Coric, Kimberley Gentile, Douglas Gray, Julia P. Gregory, Michael T. Heffernan, Robert J. Hugin, Kishen Mehta, Elyse Stock and John Tilton resigned from the board of directors of the Company.

At the Effective Time, each of Matthew Buten, George Clark, Vlad Coric, Kimberley Gentile, William Jones, Jr. and Elyse Stock resigned as officers of the Company. Pursuant to the terms of the Merger Agreement, at the Effective Time, Paloma Fern ndez-Montes Moraleda and Gast n Araya Ortega, as directors of Merger Sub as of immediately prior to the effective time of the Merger, became the directors of the Company. Additionally, Ms. Fern ndez-Montes Moraleda was appointed President of the Company, and Mr. Araya Ortega was appointed Vice President of the Company.